First reported case of khat cardiomyopathy and malignant hypertension in Australia

E. Paratz,Justin A. Mariani,A. Macisaac
DOI: https://doi.org/10.1111/imj.13283
2016-12-01
Abstract:1 Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res 2015; 5: 1602–9. 2 Daniel C, Renders L, Amann K, SchulzeLohoff E, Hauser IA, Hugo C. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849–61. 3 Nozawa M, Nonomura N, Ueda T, Nishimura K, Kanayama HO, Miki T et al. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Jpn J Clin Oncol 2013; 43: 1132–8. 4 Nakagawa S, Nishihara K, Inui K, Masuda S. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur J Pharmacol 2012; 696: 143–54. 5 Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y et al. Everolimius plus exemestane for hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 2014; 25: 2357–62.
What problem does this paper attempt to address?